What is AvantGen?
Founded in 2006 and headquartered in San Diego, AvantGen operates at the intersection of advanced biotechnology and pharmaceutical research. The company maintains a dual-focus structure, comprising a Therapeutic Division and a Research & Diagnostic division. Central to its market authority is a proprietary yeast display system, complemented by an extensive natural human antibody database and fully human Germliner libraries. These technological assets allow AvantGen to provide high-value services in antibody humanization, affinity maturation, and optimization. By facilitating partnerships and licensing agreements with major pharmaceutical entities, the firm effectively streamlines the path from discovery to clinical-stage therapeutic development.
How much funding has AvantGen raised?
AvantGen has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in AvantGen
PPP
Public-Private Partnership
What's next for AvantGen?
With the successful completion of this late-stage funding round, AvantGen is poised to scale its operational capacity and deepen its collaborative pipeline. The strategic deployment of these funds will likely focus on enhancing the throughput of its screening technologies and expanding its intellectual property portfolio. As the demand for precision antibody-based therapeutics continues to rise, AvantGen's ability to provide rapid, high-affinity solutions positions it as a critical partner for biopharma companies seeking to mitigate development risks. Future growth will likely be driven by the commercialization of its internal pipeline and the expansion of its licensing footprint in the global market.
See full AvantGen company page
